Synovus Financial Corp Has $329,000 Position in Zimmer Biomet Holdings Inc (ZBH)
Synovus Financial Corp increased its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 21.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,787 shares of the medical equipment provider’s stock after buying an additional 499 shares during the quarter. Synovus Financial Corp’s holdings in Zimmer Biomet were worth $329,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bronfman E.L. Rothschild L.P. increased its stake in shares of Zimmer Biomet by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 167 shares during the period. FNY Managed Accounts LLC purchased a new position in shares of Zimmer Biomet in the third quarter worth $117,000. BB&T Investment Services Inc. purchased a new position in Zimmer Biomet during the 2nd quarter valued at $144,000. Sandy Spring Bank increased its position in Zimmer Biomet by 5.4% during the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 66 shares during the period. Finally, Penserra Capital Management LLC increased its position in Zimmer Biomet by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,456 shares of the medical equipment provider’s stock valued at $186,000 after purchasing an additional 168 shares during the period. 86.24% of the stock is currently owned by institutional investors.
ZBH has been the topic of a number of research analyst reports. Jefferies Group reissued a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet in a research report on Friday, November 3rd. Gabelli initiated coverage on shares of Zimmer Biomet in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 price objective on the stock. Oppenheimer set a $137.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research report on Monday, August 14th. SunTrust Banks set a $136.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, Edward Jones raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $133.71.
Zimmer Biomet Holdings Inc (NYSE:ZBH) traded down $1.40 during trading hours on Friday, hitting $113.38. 1,656,416 shares of the stock were exchanged, compared to its average volume of 1,141,137. The stock has a market cap of $23,239.86, a P/E ratio of 14.22, a PEG ratio of 1.78 and a beta of 1.15. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. Zimmer Biomet Holdings Inc has a 12-month low of $100.81 and a 12-month high of $133.49.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.79 earnings per share. analysts expect that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current fiscal year.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.